Early research (Phase 1)Study completedNCT02262910What this trial is testingStudy of ES414 in Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate Cancer Aptevo Therapeutics 35
Not applicableStudy completedNCT03329742What this trial is testingSipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate CancerWho this might be right forProstate Cancer Recurrent Indiana University 2
Early research (Phase 1)Study completedNCT03569280What this trial is testingEvaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC PatientsWho this might be right forCastration-Resistant Prostate Cancer Kangpu Biopharmaceuticals, Ltd. 16
Early research (Phase 1)Study completedNCT01792687What this trial is testingSafety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetateWho this might be right forProstate Cancer Aragon Pharmaceuticals, Inc. 6
Early research (Phase 1)Looking for participantsNCT07540572What this trial is testingInvestigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsWho this might be right forER+, HER 2- Breast CancerNon-small Cell Lung Cancer (NSCLC)Castration-resistant Prostate Cancer (CRPC)+1 more IDEAYA Biosciences 160
Not applicableStudy completedNCT02380274What this trial is testingObservational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)Who this might be right forProstate CancerCastration-resistant Prostate CancerMetastatic Prostate Cancer Astellas Pharma Global Development, Inc. 1,030
Testing effectiveness (Phase 2)Study completedNCT02903160What this trial is testingProstate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)Who this might be right forProstate Cancer Icahn School of Medicine at Mount Sinai 40
Testing effectiveness (Phase 2)Ended earlyNCT01558492What this trial is testingCarboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate CancerWho this might be right forProstate Cancer Weill Medical College of Cornell University 3
Testing effectiveness (Phase 2)UnknownNCT02935205What this trial is testingEnzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate CancerWho this might be right forMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer Mamta Parikh 38
Early research (Phase 1)WithdrawnNCT02396368What this trial is testingRadium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate CancerBone-only Metastatic Castration-Resistant Prostate Cancer (CRPC) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Looking for participantsNCT07258407What this trial is testingA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate CancerWho this might be right forMetastatic Castration-Resistant Prostatic Cancer T.O.A.D. Oncology SA 180
Testing effectiveness (Phase 2)Study completedNCT01106352What this trial is testingAlpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)Who this might be right forBone MetastasesCastration-Resistant Prostate Cancer Bayer 70
Not applicableNot Yet RecruitingNCT07697989What this trial is testingPluvicto Real-world Investigation in Survival in Metastatic CRPCWho this might be right forProstatic Neoplasms, Castration-ResistantNeoplasm Metastasis Novartis Pharmaceuticals 1,085
Testing effectiveness (Phase 2)WithdrawnNCT02793765What this trial is testingDocetaxel Followed by Provenge in Metastatic Prostate CancerWho this might be right forProstate Cancer The University of Texas Health Science Center, Houston
Large-scale testing (Phase 3)Study completedNCT02887976What this trial is testingExtension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201Who this might be right forProstate Cancer GU Research Network, LLC 2
Testing effectiveness (Phase 2)UnknownNCT02266745What this trial is testingA Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsWho this might be right forAdvanced Solid TumorsCRPCmCRPC+6 more Promontory Therapeutics Inc. 109
Not applicableStudy completedNCT02376296What this trial is testingObservational Study of Docetaxel Exposure in Metastatic Prostate Cancer PatientsWho this might be right forProstate Cancer Saladax Biomedical, Inc. 35
Testing effectiveness (Phase 2)Ended earlyNCT01352208What this trial is testingPhase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) PatientsWho this might be right forCastrate Resistant Prostate Cancer Astellas Pharma Inc 13
Testing effectiveness (Phase 2)Study completedNCT03454750What this trial is testingRadiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)Who this might be right forMetastatic Castration Resistant Prostate Cancer68Ga-PSMA PET/CT Positive Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 143
Testing effectiveness (Phase 2)Looking for participantsNCT06922318What this trial is testingThe COSMYC Trial (COmbined Suppression of MYC)Who this might be right forMetastatic Castration-resistant Prostate Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50